로딩 중…
지수 로딩 중…
S.Biomedics Co., Ltd.
304360· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩18,480+5.60%
2026-08-04
Financials
Valuation Metrics
S.Biomedics Co., Ltd.'s Market Cap is ₩2289B. At end of 2025 it was ₩4700B. Ranked #748 of 2,436 in KR market (top 31%), #324 of 1,649 on KOSDAQ (top 20%), #82 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 35%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 228.88B KRW | KR#748/2,436 Sec#82/234 |
| Revenue | 16.48B KRW | KR#2,185/2,436 Sec#162/234 |
| Net Income | -7.62B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 37.49B KRW | KR#2,285/2,436 Sec#211/234 |
| Net Assets | 16.71B KRW | KR#2,317/2,436 Sec#219/234 |
| Employees | 54 | KR#2,000/2,436 Sec#181/234 |
| Value | ||
| P/B | 13.69x | KR#2,371/2,436 Sec#214/234 |
| P/S | 13.89x | KR#2,307/2,436 Sec#171/234 |
| FCF Yield | -3.65% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -45.60% | KR#2,255/2,436 Sec#195/234 |
| ROA | -20.33% | KR#2,236/2,436 Sec#178/234 |
| Op. Margin | -58.51% | KR#2,258/2,436 Sec#162/234 |
| Revenue Growth | -1.45% | KR#1,525/2,436 Sec#146/234 |
| Earnings Growth | -608.04% | KR#1,647/2,436 Sec#111/234 |
| Financial Health | ||
| Debt Ratio | 224.30% | KR#1,869/2,436 Sec#203/234 |
| Total Debt | 11.88B KRW | KR#1,558/2,436 Sec#141/234 |
| FCF | -8.35B KRW | KR#1,658/2,436 Sec#137/234 |
| Cash | 4.85B KRW | KR#2,008/2,436 Sec#184/234 |
| Current Ratio | 1.87x | KR#1,028/2,436 Sec#117/234 |
| Performance | ||
| 1Y Return | -7.46% | KR#888/2,436 Sec#67/234 |
| 1M Return | -10.94% | KR#1,819/2,436 Sec#182/234 |
| From 52W High | -56.62% | KR#1,540/2,436 Sec#131/234 |
| 1Y MDD | -62.67% | KR#1,564/2,436 Sec#124/234 |
| Trading | ||
| Volume | 47,551 shares | KR#1,353/2,436 Sec#133/234 |
| Foreign Own. | 3.78% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | -684 KRW | KR—/2,436 Sec—/234 |
| BPS | 663 KRW | KR#2,361/2,436 Sec#223/234 |
Company Info
동사는 2003년 설립 후 2005년 줄기세포치료제 개발 사업으로 전환했으며, 종속회사 에스테팜은 2016년 설립되어 필러와 화장품을 제조·판매하고 있음. 동사는 줄기세포 분화기술과 3차원 세포집합체 기술을 활용해 다양한 질환 영역에서 세포치료제를 개발 중임. 배아줄기세포를 이용한 치료제는 세계적으로 드물어 주요국들과 경쟁하며 차별화된 생산기술로 임상 성공 가능성을 높이고 있음. 에스바이오메딕스는 2003년에 설립되었으며 서울특별시 성동구에 본사를 두고 있습니다.